Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATRA 
Atara Biotherapeutics Inc (ATRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ATRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.07% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.21M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 62820 | Beta 0.49 | 52 Weeks Range 5.40 - 20.81 | Updated Date 04/2/2025 |
52 Weeks Range 5.40 - 20.81 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.41 |
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -3.4875 | Actual -1.19 |
Profitability
Profit Margin -66.24% | Operating Margin (TTM) -37.26% |
Management Effectiveness
Return on Assets (TTM) -35.66% | Return on Equity (TTM) -2014.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36547043 | Price to Sales(TTM) 0.27 |
Enterprise Value 36547043 | Price to Sales(TTM) 0.27 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -0.35 | Shares Outstanding 5858910 | Shares Floating 4203298 |
Shares Outstanding 5858910 | Shares Floating 4203298 | ||
Percent Insiders 21.73 | Percent Institutions 50.5 |
Analyst Ratings
Rating 4.33 | Target Price 16.5 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Atara Biotherapeutics Inc
Company Overview
History and Background
Atara Biotherapeutics, Inc. was founded in 2012. It focuses on developing allogeneic T-cell immunotherapies for cancer, autoimmune, and viral diseases. It has progressed through clinical trials for several product candidates.
Core Business Areas
- Allogeneic T-Cell Immunotherapies: Developing off-the-shelf T-cell immunotherapies sourced from healthy donors for various diseases.
Leadership and Structure
The company has a board of directors and an executive leadership team led by the CEO. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Tabelecleucel (Tab-cel): An allogeneic T-cell immunotherapy targeting Epstein-Barr virus (EBV)-driven diseases. It is approved in Europe for certain EBV+ PTLD. Competitors include other cell therapy companies and established treatments for EBV-related diseases. Revenue data for the product is still evolving.
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, driven by advancements in immunotherapy and gene editing. The market is competitive, with numerous companies developing novel therapies.
Positioning
Atara Biotherapeutics is positioned as a leader in allogeneic T-cell immunotherapy, focusing on EBV and other viral-associated cancers. Competitive advantages include its Allo-T platform and clinical trial progress.
Total Addressable Market (TAM)
The TAM for cell therapies is projected to reach billions of dollars. Atara targets specific segments of this market, focusing on EBV-driven cancers and autoimmune diseases.
Upturn SWOT Analysis
Strengths
- Allogeneic T-cell platform
- Clinical trial progress with Tab-cel
- Experienced management team
- Partnerships with leading institutions
Weaknesses
- Dependence on clinical trial outcomes
- High cash burn rate
- Limited commercial product revenue
- Regulatory hurdles
Opportunities
- Expansion of Tab-cel indications
- Development of new allogeneic T-cell therapies
- Strategic partnerships and collaborations
- Advancements in manufacturing technologies
Threats
- Competition from other cell therapy companies
- Clinical trial failures
- Regulatory setbacks
- Funding challenges
Competitors and Market Share
Key Competitors
- GILD
- BMY
- JNJ
Competitive Landscape
Atara faces competition from companies with established cell therapy platforms and treatments for viral-associated diseases. Its allogeneic approach offers potential advantages in scalability and accessibility.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by clinical trial progress and strategic collaborations.
Future Projections: Future growth depends on regulatory approvals and commercialization efforts.
Recent Initiatives: Recent initiatives include expanding clinical trials and pursuing regulatory approvals for Tab-cel.
Summary
Atara Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic T-cell immunotherapies. The company has made progress with Tab-cel and its Allo-T platform, but faces challenges in regulatory approvals and commercialization. It needs to monitor competition in the cell therapy space and manage its cash burn. Success hinges on positive clinical trial outcomes and strategic partnerships.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atara Biotherapeutics Inc
Exchange NASDAQ | Headquaters Thousand Oaks, CA, United States | ||
IPO Launch date 2014-10-16 | President, CEO & Director Dr. Anhco Nguyen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 153 | Website https://www.atarabio.com |
Full time employees 153 | Website https://www.atarabio.com | ||
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.